Please assess the completion status of the following clinical trial:

Trial Title: Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject and/or parent guardian must be able to understand and provide informed consent;~* Is the recipient of a living or deceased donor liver tx when subject was less than or equal to 6 years of age;~* Is at least 4 years post-tx at the time of study enrollment;~* Has normal allograft function defined as Alanine aminotransferase (ALT) \< 50 IU/l and gamma-glutamyl transferase (GGT) \< 50 IU/l;~* Has no evidence of acute rejection (AR) or chronic rejection (CR) within the past 2 years, based on medical history;~* Is stable on IS monotherapy with a calcineurin inhibitor (CNI);~* For female subjects of childbearing potential, subject must have a negative pregnancy test upon study entry;~* For female and male subjects with reproductive potential, subject must agree to use FDA approved methods of birth control for the duration of the study;~* Must be negative for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection within one year of enrollment;~* Must have screening biopsy that fulfills, based on central pathology reading, the following criteria:~  * Portal inflammation and interface activity: Preferably absent, but minimal to focal mild portal mononuclear inflammation may be present. Interface necro-inflammatory activity is absent or equivocal/minimal and, if present, involves a minority of portal tracts.~ * Centrizonal/peri-venular inflammation: Preferably absent, but minimal to focal mild perivenular mononuclear inflammation may be present. Perivenular necro-inflammatory activity is absent or equivocal/minimal and, if present, involves a minority of terminal hepatic venules.~ * Bile duct changes: No lymphocytic bile duct damage, ductopenia and biliary epithelial senescence changes, unless there is an alternative, non-immunologic explanation (e.g. biliary strictures).~ * Fibrosis: \< Ishak Stage 3 (i.e. not more than occasional portal-to-portal bridging). Perivenular fibrosis should be less than moderate, according to Banff Criteria.~ * Arteries: Negative for obliterative or foam cell arteriopathy.~Exclusion Criteria:~* Have received a liver tx for autoimmune liver disease, including autoimmune hepatitis or primary sclerosing cholangitis;~* Have received a liver tx for hepatitis B or hepatitis C;~* Have received a second organ transplant before, simultaneously, or after liver tx;~* Have a calculated glomerular filtration rate (modified Schwartz formula) of less than 60 mL/min/1.73 m\^2;~* Have had a 50 percent (%) dose increase in CNI within 6 months of screening;~* Have discontinued a second IS agent within 12 months of screening;~* Have any systemic illness requiring or likely to require chronic or recurrent use of IS;~* Is pregnant or breastfeeding;~* Is unwilling or unable to adhere with study requirements and procedures;~* Have mental illness or history of drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements;~* Is unwilling or unable to provide consent or comply with the study protocol;~* Has used investigational drugs within 4 weeks of enrollment;~* Is receiving treatment for HIV infection;~* Has received any licensed or investigational live attenuated vaccine(s) within two months of enrollment;~* Has any medical condition that, in the opinion of the investigator, will interfere with safe participation in the trial.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Immunosuppression withdrawal (Type: EXPERIMENTAL): Gradual withdrawal of immunosuppressive treatment withdrawal as per protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).